Andrea Puppo

Dr. Andrea Puppo

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
JCJvan Casarin
Jvan Casarin
GBGiorgio Bogani
Giorgio Bogani
EPElisa Piovano
Elisa Piovano
FFFrancesca Falcone
Francesca Falcone
FFFederico Ferrari
Federico Ferrari
FGFabio Ghezzi
Fabio Ghezzi
Casarin J, et al. J Gynecol Oncol. 2019 Jun;31:e64. https://doi.org/10.3802/jgo.2020.31.e64

27 September 2005 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MCMaria G Centurioni
Maria G Centurioni
APAndrea Puppo
Andrea Puppo
DMDomenico F Merlo
Domenico F Merlo
GPGennaro Pasciucco
Gennaro Pasciucco
ECEnzo R Cusimano
Enzo R Cusimano
CGClaudio A Gustavino
Claudio A Gustavino
Background: In the last decade many studies have definitely shown that human papillomaviruses (HPVs) are the major cause of cervical carcinogenesis and, in the last few years, HPV testing has been proposed as a new and more powerful tool for cervical cancer screening. This issue is now receiving considerable attention in scientific and non scientific press and HPV testing could be considered the most important change in this field since the introduction of cervical cytology. This paper reports our prevalence data of HPV infection collected in the '90s, while a follow up of these patients is ongoing. Methods: For this study we used polymerase chain reaction (PCR) to search HPV DNA sequences in cervical cell scrapings obtained from 503 asymptomatic women attending regular cervical cancer screening program in the city of Genova, Italy. All patients were also submitted to a self-administered, standardized, questionnaire regarding their life style and sexual activity. On the basis of the presence of HPV DNA sequences women were separated into two groups: "infected" and "non infected" and a statistical analysis of the factors potentially associated with the infection group membership was carried out. Results: The infection rate was 15.9% and the most frequent viral type was HPV 16. Conclusion: Our HPV positivity rate (15.9%) was consistent to that reported by other studies on European populations.

4 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Alessandro BudaAlessandro Buda
Alessandro Buda
MBMartina Borghese
Martina Borghese
APAndrea Puppo
Andrea Puppo
SPStefania Perotto
Stefania Perotto
ANAntonia Novelli
Antonia Novelli
Francesco FanfaniFrancesco Fanfani
Francesco Fanfani
Nowadays, the optimal management of patients with cervical cancers measuring 2–4 cm desiring to maintain fertility is still uncertain. In this systematic review, we assessed the reliability of neoadjuvant chemotherapy (NACT) prior to fertility-sparing (FS) surgery in International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB2 cervical cancer, in terms of pathologic response, oncological and obstetric outcomes. The review of the literature was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data, using MEDLINE and PubMed, were searched for from 1 January 2005 up to 1 December 2020. We identified 20 articles and 114 women with IB2 disease, possible candidates for NACT prior to FS surgery. However, uterine conservation was achieved only in 76.7% of them. Patients reached optimal pathological response to NACT in 60.9% of cases and a TIP (cisplatin, ifosfamide and paclitaxel) regime was related to the best response. Suboptimal response to NACT appeared to be an independent negative prognostic factor. Up to 9.2% of patients recurred with a median 7.4-months DFS, and 4.6% of patients died of disease. Fifty percent of women tried to conceive after treatment and NACT prior to conization appeared to be the most promising alternative to upfront radical trachelectomy in terms of obstetric outcomes. In conclusion, NACT prior to FS surgery is an option, but the literature about this issue is still weak and FS should be carefully discussed with patients.

30 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Alessandro BudaAlessandro Buda
Alessandro Buda
CPCristiana Paniga
Cristiana Paniga
STSalih Taskin
Salih Taskin
MMMichael Mueller
Michael Mueller
Ignacio ZapardielIgnacio Zapardiel
Ignacio Zapardiel
RFRobert Fruscio
Robert Fruscio
The aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an international collaboration including 13 referring institutions. A total of 1428 patients were included in this analysis. One hundred and eighty-six patients (13%) had lymph node involvement. Fifty-nine percent of positive SLN exhibited micrometastases, 26.9% micrometastases, and 14% isolated tumor cells. Seventeen patients with positive lymph nodes did not receive any adjuvant therapy. At a median follow-up of 33.3 months, the disease had recurred in 114 women (8%). Patients with micrometastases in the lymph nodes had a worse prognosis of disease-free survival compared to patients with negative nodes or LVM. The rate of recurrence was significantly higher for women with micrometastases than those with low-volume metastases (HR = 2.61; p = 0.01). The administration of adjuvant treatment in patients with LVM, without uterine risk factors, remains a matter of debate and requires further evaluation.

14 March 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
Alessandro BudaAlessandro Buda
Alessandro Buda
GMGiampaolo Di Martino
Giampaolo Di Martino
MBMartina Borghese
Martina Borghese
Stefano RestainoStefano Restaino
Stefano Restaino
ASAlessandra Surace
Alessandra Surace
RFRobert Fruscio
Robert Fruscio
The aim of our study was to evaluate the benefits of a low-pressure insufflation system (AirSeal) vs. a standard insufflation system in terms of anesthesiologists’ parameters and postoperative pain in patients undergoing laparoscopic surgery for early-stage endometrial cancer. This retrospective study involved five tertiary centers and included 152 patients with apparent early-stage disease who underwent laparoscopic surgical staging with either the low-pressure AirSeal system (8–10 mmHg, n = 84) or standard laparoscopic insufflation (10–12 mmHg, n = 68). All the intraoperative anesthesia variables evaluated (systolic blood pressure, end-tidal CO2, peak airway pressure) were significantly lower in the AirSeal group. We recorded a statistically significant difference between the two groups in the median NRS scores for global pain recorded at 4, 8, and 24 h, and for overall shoulder pain after surgery. Significantly more women in the AirSeal group were also discharged on day one compared to the standard group. All such results were confirmed when analyzing the subgroup of women with a BMI >30 kg/m2. In conclusion, according to our preliminary study, low-pressure laparoscopy represents a valid alternative to standard laparoscopy and could facilitate the development of outpatient surgery.

1 January 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
GBGiorgio Bogani
Giorgio Bogani
GSGiovanni Scambia
Giovanni Scambia
CCChiara Cimmino
Chiara Cimmino
FFFrancesco Fanfani
Francesco Fanfani
BCBarbara Costantini
Barbara Costantini
FRFrancesco Raspagliesi
Francesco Raspagliesi
Bogani G, et al. J Gynecol Oncol. 2021 Nov;33(1):e10. https://doi.org/10.3802/jgo.2022.33.e10